AnaptysBio, Inc. (ANAB)
NASDAQ: ANAB · IEX Real-Time Price · USD
34.61
+0.91 (2.70%)
Jul 22, 2024, 10:23 AM EDT - Market open
AnaptysBio Employees
AnaptysBio had 117 employees as of December 31, 2023. The number of employees increased by 21 or 21.88% compared to the previous year.
Employees
117
Change (1Y)
21
Growth (1Y)
21.88%
Revenue / Employee
$196,256
Profits / Employee
-$1,395,726
Market Cap
940.85M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
HealthStream | 1,092 |
Pacira BioSciences | 712 |
CareDx | 643 |
BioLife Solutions | 414 |
Cronos Group | 356 |
Bicycle Therapeutics | 284 |
Silence Therapeutics | 109 |
Viridian Therapeutics | 94 |
ANAB News
- 2 months ago - Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP) - GlobeNewsWire
- 2 months ago - Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties - GlobeNewsWire
- 3 months ago - Actym Therapeutics Appoints Thomas Smart as CEO - PRNewsWire
- 4 months ago - Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update - GlobeNewsWire
- 5 months ago - Anaptys to Present at TD Cowen's 44th Annual Health Care Conference and 2024 AAD Annual Meeting - GlobeNewsWire
- 6 months ago - Anaptys to Present at Guggenheim's 6th Annual Biotechnology Conference - GlobeNewsWire
- 8 months ago - Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals - GlobeNewsWire